ARTV · Artiva Biotherapeutics, Inc.

Looking forward, management anticipates significantly increasing expenses and capital needs as it advances lead product candidates and other programs, compounded by public company costs. Research and development outlays are expected to rise substantially with planned preclinical and clinical activities. However, existing cash, cash equivalents, and investments are projected to fund operating expenses and capital requirements into Q2 2027 under current plans. This runway provides a bridge for key milestones, though investors should monitor R&D trajectory and funding dynamics closely.